Shares of Kura Oncology Inc. (NASDAQ:KURA) have earned an average broker rating score of 1.00 (Strong Buy) from the two brokers that provide coverage for the company, Zacks Investment Research reports. Two analysts have rated the stock with a strong buy rating.
Analysts have set a 12 month consensus price target of $20.00 for the company and are forecasting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also assigned Kura Oncology an industry rank of 86 out of 265 based on the ratings given to related companies.
KURA has been the subject of several analyst reports. Oppenheimer Holdings Inc. restated an “outperform” rating and issued a $16.00 target price on shares of Kura Oncology in a report on Tuesday, June 21st. Zacks Investment Research upgraded Kura Oncology from a “sell” rating to a “hold” rating in a report on Tuesday, August 23rd.
Kura Oncology (NASDAQ:KURA) opened at 7.00 on Tuesday. Kura Oncology has a 52 week low of $2.50 and a 52 week high of $25.00. The company’s 50-day moving average price is $5.69 and its 200 day moving average price is $4.01. The company’s market capitalization is $131.20 million.
Kura Oncology (NASDAQ:KURA) last announced its quarterly earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.34) by $0.02. On average, equities research analysts anticipate that Kura Oncology will post ($1.58) EPS for the current year.
An institutional investor recently bought a new position in Kura Oncology stock. Minerva Advisors LLC purchased a new stake in Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor purchased 361,737 shares of the company’s stock, valued at approximately $977,000. Minerva Advisors LLC owned approximately 1.96% of Kura Oncology as of its most recent SEC filing. 43.63% of the stock is currently owned by hedge funds and other institutional investors.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Kura Oncology Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kura Oncology Inc. and related companies with MarketBeat.com's FREE daily email newsletter.